Publications by authors named "Martin Polinsky"

Claim this Profile
A
Abatacept for acute graft-versus-host disease prophylaxis after unrelated donor hematopoietic cell transplantation.
Leslie S Kean, Linda J Burns, Tzuyung D Kou, Roxanne Kapikian, Karissa Lozenski, Martin Polinsky

Blood· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term Safety in Epstein-Barr Virus-Seropositive Kidney-only Transplant Recipients Treated With Belatacept in Clinical Practice: Final Study Results From the ENLiST Registry.
Christian P Larsen, Flavio Vincenti, Tzuyung D Kou, Craig A Shadur, Barbara Bresnahan, Martin S Polinsky

Transplant Direct· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of De Novo Renal Transplant Recipients With Calcineurin Inhibitor-free, Belatacept Plus Everolimus-based Immunosuppression.
V Ram Peddi, Bradley Marder, Luis Gaite, Jose Oberholzer, Ryan Goldberg, Martin Polinsky

Transplant Direct· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conversion from Calcineurin Inhibitor- to Belatacept-Based Maintenance Immunosuppression in Renal Transplant Recipients: A Randomized Phase 3b Trial.
Klemens Budde, Rohini Prashar, Hermann Haller, Maria C Rial, Nassim Kamar, Martin Polinsky

J Am Soc Nephrol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HLA-DRB1 risk alleles for RA are associated with differential clinical responsiveness to abatacept and adalimumab: data from a head-to-head, randomized, single-blind study in autoantibody-positive early RA.
William Rigby, Jane H Buckner, S Louis Bridges, Marleen Nys, Sheng Gao, Martin Polinsky

Arthritis Res Ther· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trajectories of health-related quality of life among renal transplant patients associated with graft failure and symptom distress: Analysis of the BENEFIT and BENEFIT-EXT trials.
Intan Purnajo, Jennifer L Beaumont, Martin Polinsky, Evo Alemao, Matthew J Everly

Am J Transplant· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of single-dose pharmacokinetics and pharmacodynamics of belatacept in adolescent kidney transplant recipients.
Asha Moudgil, Vikas R Dharnidharka, Daniel I Feig, Barry L Warshaw, Vidya Perera, Martin S Polinsky

Am J Transplant· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes at 7 years post-transplant in black vs nonblack kidney transplant recipients administered belatacept or cyclosporine in BENEFIT and BENEFIT-EXT.
Sander Florman, Flavio Vincenti, Antoine Durrbach, Marwan Abouljoud, Barbara Bresnahan, Martin Polinsky

Clin Transplant· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Tolerability Study of an Intravenously Administered Small Interfering Ribonucleic Acid (siRNA) Post On-Pump Cardiothoracic Surgery in Patients at Risk of Acute Kidney Injury.
Segav Demirjian, Gorav Ailawadi, Martin Polinsky, Dani Bitran, Shuli Silberman

Kidney Int Rep· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Belatacept and Long-Term Outcomes in Kidney Transplantation.
Flavio Vincenti, Lionel Rostaing, Joseph Grinyo, Kim Rice, Steven Steinberg, Martin S Polinsky

N Engl J Med· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial.
Josefina Alberú, Michael D Pascoe, Josep M Campistol, Francesco P Schena, Maria Del Carmen Rial, Martin Polinsky

Transplantation· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
Francesco P Schena, Michael D Pascoe, Josefina Alberu, Maria del Carmen Rial, Rainer Oberbauer, Martin S Polinsky

Transplantation· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Accuracy and variability of equations to estimate glomerular filtration rates in renal transplant patients receiving sirolimus and/or calcineurin inhibitor immunosuppression.
James T Burke, Yves Brault, Barry D Kahan, Donald E Hricik, Josep M Grinyó, Martin Polinsky

Transpl Int· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dietary protein intake significantly affects the serum creatinine concentration.
Lavjay Butani, Martin S Polinsky, Bruce A Kaiser, H Jorge Baluarte

Kidney Int· May 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis